After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...